Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 7:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 3,302 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diseases of the Circulatory System Clear all
Active, not recruiting Not applicable Interventional

Safety of the Sonablate HIFU System for the Ablation of Incompetent Veins of the Periphery

NCT06642051
View directory record Official record
Conditions
Chronic Venous Insufficiency, CVI, Venous Malformations, Venous Leg Ulcers, Klippel-Trenaunay Syndrome, CLOVES Syndrome, Blue Rubber Bleb Nevus Syndrome
Interventions
High Intensity focused ultrasound
Device
Lead sponsor
Sonablate
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Darien, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 14, 2026, 7:36 AM EDT
Completed Phase 2 Interventional

The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers

NCT00001873
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Graft vs Host Disease, Hematologic Neoplasm, Multiple Myeloma, Myelodysplastic Syndrome
Interventions
Isolex 300i plus MoAbs
Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
10 Years to 55 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Oct 14, 2026, 7:36 AM EDT
Completed Phase 3 Interventional

A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease

NCT01018173
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
placebo, taspoglutide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
2,118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
76
States / cities
Phoenix, Arizona • Tucson, Arizona • Buena Park, California + 67 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 14, 2026, 7:36 AM EDT
Completed Phase 3 Interventional

Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy

NCT00130845
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Octreotide Acetate in Microspheres, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 17, 2011 · Synced Oct 14, 2026, 7:36 AM EDT
Terminated Phase 3 Interventional

Phase 3 Study Evaluating Efficacy and Safety of DSC127 Compared With Vehicle and With Standard-of-care in Diabetic Foot Ulcers

NCT01849965
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
DSC127, placebo vehicle gel, Standard of Care gel, Aquasite
Drug
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
33
States / cities
Mesa, Arizona • Phoenix, Arizona • Castro Valley, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 14, 2026, 7:36 AM EDT
Completed Phase 2 Interventional Results available

A Dose-range Finding Study of MAA868 in Patients With Atrial Fibrillation

NCT04213807
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
MAA868 Cohort 1, MAA868 Cohort 2, MAA868 Cohort 3, Placebo
Biological · Other
Lead sponsor
Anthos Therapeutics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
6
States / cities
Beverly Hills, California • Wichita, Kansas • Alexandria, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 14, 2026, 7:36 AM EDT
Completed Not applicable Interventional Results available

SYMPHONY-PE Study for Treatment of Pulmonary Embolism

NCT06062329
View directory record Official record
Conditions
Acute Pulmonary Embolism, Thromboembolism, Emboli, Pulmonary, Thrombosis, Thrombus; Embolism, Embolism, Cardiovascular Diseases, Vascular Diseases
Interventions
Symphony Thrombectomy System
Device
Lead sponsor
Imperative Care, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
19
States / cities
Huntsville, Alabama • Los Angeles, California • Jacksonville, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 14, 2026, 7:36 AM EDT
Terminated Phase 1Phase 2 Interventional

Safety and Efficacy of Gentamicin Topical Gel (AppliGel-G) for Treatment of Mild to Moderately Infected Diabetic Foot Ulcers

NCT02036528
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
Gentamicin Topical Gel, Ciprofloxacin, Doxycycline
Drug
Lead sponsor
Royer Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Miami, Florida • Miami Lakes, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 14, 2015 · Synced Oct 14, 2026, 7:36 AM EDT
Completed No phase listed Observational

A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy ,DR)

NCT04477707
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Finerenone (BAY94-8862)
Drug
Lead sponsor
Bayer
Industry
Eligibility
Not listed
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
10
States / cities
Chula Vista, California • El Centro, California • Fort Lauderdale, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Oct 14, 2026, 7:36 AM EDT
Completed Phase 1 Interventional

Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies

NCT01094860
View directory record Official record
Conditions
Leukemia
Interventions
Nelarabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Oct 14, 2026, 7:36 AM EDT
Completed Not applicable Interventional

Laughter Therapy Effects on Mood, Stress and Self-efficacy in People With Neurological Diseases.

NCT02750982
View directory record Official record
Conditions
Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Brain Injury, Huntington's Disease, Multiple Sclerosis, Parkinson's Disease, Stroke, Spinal Cord Injury
Interventions
Laughter Therapy
Other
Lead sponsor
Brown, Theodore R., M.D., MPH
Individual
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Oct 14, 2026, 7:36 AM EDT
Terminated Phase 2 Interventional

Study of Low Intensity Conditioning and Immunotherapy for High-Risk Cancers of the Blood

NCT00143884
View directory record Official record
Conditions
Leukemia, Lymphoma, Low-Grade, Lymphoma, Non-Hodgkin's, Multiple Myeloma, Myelodysplastic Syndromes
Interventions
Reduced intensity conditioning, Prophylactic donor leukocyte infusions
Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 23, 2007 · Synced Oct 14, 2026, 7:36 AM EDT
Completed Not applicable Interventional Results available

COMPASSION - COngenital Multicenter Trial of Pulmonic VAlve Regurgitation Studying the SAPIEN InterventIONal THV

NCT00676689
View directory record Official record
Conditions
Pulmonary Valve Insufficiency, Pulmonary Regurgitation, Dysfunctional RVOT Conduit, Pulmonary Obstruction, Pulmonary Stenosis
Interventions
SAPIEN Transcatheter Valve Implantation
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
Not listed
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
7
States / cities
Los Angeles, California • Miami, Florida • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Oct 14, 2026, 7:36 AM EDT
Completed No phase listed Observational

Sensitivity to Change of the Lower Extremity Functional Scale in Patients With Stroke

NCT01536990
View directory record Official record
Conditions
Lower Extremity Dysfunction, Stroke
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 99 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Oct 14, 2026, 7:36 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Pathogenesis of Primary Ciliary Dyskinesia (PCD) Lung Disease

NCT00807482
View directory record Official record
Conditions
Kartagener Syndrome
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
Not listed
Enrollment
1,800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 14, 2026, 7:36 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Evaluation of Implementation of a National Point-of-Care Ultrasound Training Program

NCT03296280
View directory record Official record
Conditions
Other Acute Illnesses Presenting to the Hospital, Heart Failure, Pneumonia, Deep Venous Thrombosis, Cellulitis, Abdominal Aortic Aneurysm, Acute Cholecystitis, Peritoneal Free Fluid, Hydronephrosis, Pleural Effusion, Urinary Retention
Interventions
Not listed
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 14, 2026, 7:36 AM EDT
Completed Phase 1Phase 2 Interventional

Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

NCT02649790
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Higher-Risk Myelodysplastic Syndrome (HR-MDS), Acute Myeloid Leukemia (AML), Newly Diagnosed Intermediate/High-Risk MDS
Interventions
KPT-8602, ASTX727, Dexamethasone
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
26
States / cities
Los Angeles, California • Pasadena, California • Aurora, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Oct 14, 2026, 7:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

ASAP: Access to Syringes at Pharmacies for the Prevention of Bloodborne Infections Among People Who Inject Drugs

NCT05270135
View directory record Official record
Conditions
Skin and Soft Tissue Infections, Hiv, Hepatitis C, Bloodstream Infection
Interventions
ASAP
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Oct 14, 2026, 7:36 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety Study of Dantrolene to Treat Cerebral Vasospasm After Subarachnoid Hemorrhage

NCT00964548
View directory record Official record
Conditions
Cerebral Vasospasm After Subarachnoid Hemorrhage
Interventions
Dantrolene
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Boston, Massachusetts • Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 25, 2012 · Synced Oct 14, 2026, 7:36 AM EDT
Completed Not applicable Interventional Results available

Clinical Study of the L300 Versus Ankle-foot Orthosis (AFO) on Post-Stroke Subjects With Foot Drop

NCT01138995
View directory record Official record
Conditions
Sensorimotor Gait Disorder, Neurologic Ambulation Disorder, Gait, Drop Foot, Poststroke Hemiparesis, Post-Cerebrovascular Accident (CVA) Hemiparesis
Interventions
Ness L300, Ankle-foot orthosis
Device
Lead sponsor
Bioness Inc
Industry
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
11
States / cities
Downey, California • Long Beach, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2016 · Synced Oct 14, 2026, 7:36 AM EDT
Completed Not applicable Interventional

ENRICH: Early MiNimally-invasive Removal of IntraCerebral Hemorrhage (ICH)

NCT02880878
View directory record Official record
Conditions
Intracerebral Hemorrhage, Cerebral Hemorrhage, Intracerebral Haemorrhage
Interventions
Early Surgical Hematoma Evacuation
Procedure
Lead sponsor
Nico Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Oct 14, 2026, 7:36 AM EDT
Completed No phase listed Observational

Repeatability and Reproducibility of the CADence™System

NCT03793049
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
CADence testing will be performed
Device
Lead sponsor
AUM Cardiovascular, Inc.
Industry
Eligibility
22 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
3
States / cities
Minneapolis, Minnesota • Northfield, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Oct 14, 2026, 7:36 AM EDT
Terminated Phase 2 Interventional Results available

A Trial to Evaluate the Efficacy and Safety of Different Doses of KVD824 for Prophylactic Treatment of HAE Type I or II

NCT05055258
View directory record Official record
Conditions
Angioedema, Hereditary, Types I and II
Interventions
KVD824, Placebo to KVD824
Drug
Lead sponsor
KalVista Pharmaceuticals, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
13
States / cities
Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 14, 2026, 7:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Identifying the Anti-Blood-Clotting Compounds in Garlic

NCT00200785
View directory record Official record
Conditions
Arteriosclerosis, Intracranial Arteriosclerosis
Interventions
garlic powder added to ambient water, garlic powder added to boiling water
Dietary Supplement
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Orem, Utah
Source: ClinicalTrials.gov public record
Updated Jan 11, 2010 · Synced Oct 14, 2026, 7:36 AM EDT